Advisor Partners’s CONMED CNMD Stock Holding History

Advisor Partners’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,362	Closed	-$202K	–	847
2022 Q1	$202K	Buy	+1,362	New	+$190K	0.01%	836

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Advisor Partners's CNMD Position: Q2 2022 in Review

Advisor Partners sold out of CONMED (CNMD) in Q2 2022, closing a stake of 1,362 shares — an estimated $202K sold.

Advisor Partners first reported a position in CNMD in Q1 2022 and held it in 1 quarter. The position peaked at $202K in Q1 2022. 280 funds tracked by Wall St. Rank hold CNMD as of Q2 2022.

Advisor Partners reported no remaining CONMED position as of Q2 2022 after selling out during the quarter.
Advisor Partners sold 1,362 CONMED shares in Q2 2022, an estimated $202K.
Advisor Partners first reported a position in CONMED in Q1 2022 and held it in 1 quarter.
Advisor Partners's CONMED position peaked at $202K in Q1 2022.
280 funds tracked by Wall St. Rank held CONMED as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.